HonCode

Go Back   HER2 Support Group Forums > Breast Cancer Meeting Highlights
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Breast Cancer Meeting Highlights News fro recent ASCO and San Antonio Meetings

Reply
 
Thread Tools Display Modes
Old 05-20-2014, 07:36 AM   #1
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Post AE37 vaccine

Generex Announces Presentation of Primary Efficacy Data & Immunological Response from the Phase II Study of AE37 Cancer Vaccine at ASCO - Tuesday, May 20, 2014

WORCESTER, Mass. and TORONTO, May 20, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced two upcoming presentations demonstrating that certain patients with early stage breast cancer who receive AE37 may benefit in terms of reduced risk of relapse. The AE37 breast cancer vaccine is being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The presentations will be made at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago from May 30 through June 3, 2014.
The Company recently reported completion of accrual to a prospective, randomized, controlled and single-blinded Phase II study of AE37 in newly diagnosed breast cancer patients. Prior interim analysis revealed a strong trend toward reduction of relapse in patients with low to intermediate levels of HER2 expression.
AE37 was designed to generate a robust response to the HER2 protein, particularly in CD4+ T helper cells, which have been shown to be critical in the generation of a new immune response. The results of two Phase I studies, in breast and prostate cancer patients respectively, previously demonstrated robust and specific immune stimulation. AE37 has been shown to be safe and well-tolerated by patients in all trials.
The first presentation entitled "Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine vs GM-CSF alone administered in the adjuvant setting to high risk breast cancer patients" by Mittendorf et al, demonstrates that patients with low to intermediate levels of HER2 expression displayed a trend toward benefit from the AE37 vaccine, as was initially observed from the interim analysis of the same study. In particular, patients with triple negative breast cancer appeared to derive the greatest benefit. Patients in the low HER2 group exhibited a 40% decrease in the risk of relapse (p=0.21) while those with triple negative cancer exhibited a 60% decreased risk (p=0.12).
The second presentation, entitled "Immunogenic Comparison of Recurrent and Non-Recurrent Breast Cancer Patients Undergoing AE37 Peptide Vaccine Therapy" by Schnebel et al, showed a correlation between the magnitude of immunological response to AE37 and the tendency to relapse. Prior studies have shown that AE37 generates a more robust immune response than other HER2 targeted peptide vaccines, with AE37 being the only vaccine capable of generating a specific immunogenicity in the absence of GM-CSF adjuvant.
"We remain encouraged by the overall AE37 clinical data package" said Dr. Eric von Hofe, Ph.D., President of Antigen Express. "The robustness of the immunological response, together with a trend toward reduced relapse in patients with low HER2 expression, and particularly those with triple-negative breast cancer, is promising," he continued. The lack of effective treatments for triple negative breast cancer patients has long been recognized as a major area of unmet medical need.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
'lizbeth is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 12:17 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2018, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter